Differential analysis of genetic mutations showed FLT3, TP53, MUC16, SRSF2, and KDM5A mutated more frequently (p < 0.050) in secondary acute myeloid leukemia (s‐AML) than in MDS and MPN. This evidence concerns the gene TP53 and myeloproliferative disorder.